Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
125.23
-0.14 (-0.11%)
Official Closing Price
Updated: 7:00 PM EDT, Apr 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
5,992,703
Open
125.52
Bid (Size)
125.25 (1)
Ask (Size)
126.80 (1)
Prev. Close
125.37
Today's Range
124.50 - 125.52
52wk Range
99.14 - 133.10
Shares Outstanding
2,531,374,696
Dividend Yield
2.33%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Unveiling 17 Analyst Insights On Merck & Co
Today 14:01 EDT
Via
Benzinga
Market Whales and Their Recent Bets on MRK Options
April 17, 2024
Via
Benzinga
Performance
YTD
+10.59%
+10.59%
1 Month
+2.48%
+2.48%
3 Month
+5.64%
+5.64%
6 Month
+24.69%
+24.69%
1 Year
+9.73%
+9.73%
More News
Read More
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
April 17, 2024
Via
InvestorPlace
Exposures
Product Safety
3 Dow Stocks to Buy Now: Q2 Edition
April 16, 2024
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
April 16, 2024
Via
Talk Markets
Better Growth Play: Merck or The Vanguard Growth Index Fund?
April 15, 2024
Via
The Motley Fool
When you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
April 11, 2024
Via
Chartmill
Understanding Merck & Co's Position In Pharmaceuticals Industry Compared To Competitors
April 08, 2024
Via
Benzinga
2 Dividend Stocks to Buy and Hold Forever
April 08, 2024
Via
The Motley Fool
Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.
April 14, 2024
Via
The Motley Fool
1 New Green Flag for Moderna and Merck Stock
April 12, 2024
Via
The Motley Fool
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
April 12, 2024
Via
InvestorPlace
Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans
April 11, 2024
Via
Benzinga
Exposures
COVID-19
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
April 11, 2024
Via
InvestorPlace
Market Whales and Their Recent Bets on MRK Options
April 03, 2024
Via
Benzinga
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
April 10, 2024
Via
Benzinga
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
April 10, 2024
Via
Benzinga
Why Is Moderna Stock Trading Higher On Tuesday?
April 09, 2024
Via
Benzinga
Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement
April 08, 2024
Via
InvestorPlace
Topics
Retirement
Exposures
Pension
Down 75%. Is Agenus Stock a Buy on the Dip?
April 08, 2024
Via
The Motley Fool
The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024
April 07, 2024
Via
InvestorPlace
Topics
Economy
Stocks
Exposures
Economy
US Equities
10 Health Care Stocks Whale Activity In Today's Session
April 04, 2024
Via
Benzinga
Cancer-Focused eFFECTOR Therapeutics Shelves Development Of Lung Cancer Candidate After Disappointing Data
April 04, 2024
Via
Benzinga
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
April 04, 2024
From
Merck & Co., Inc.
Via
Business Wire
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
April 03, 2024
From
Daiichi Sankyo
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.